Supplementary Figure S3 from MAPK Pathway–Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial
Year: 2025
Type: supplementary-materials
Abstract: Supplementary Figure 3. Median duration of response. NI group (blue line) vs N-CT group (red line). N-CT: nivolumab plus platinum-based chemotherapy; NI: nivolumab plus ipilimumab.
Authors: Federico Cappuzzo, Biagio Ricciuti, Angelo Delmonte, Laura Bonanno, Xiaoyue Wang, Weng Kit Lye, Andreas Görtz, Kalliopi Andrikou, Alessandro Dal Maso, Gabriele Minuti, Maximilian Papi, Joao Victor Alessi, Alessandro Di Federico, Scott Rodig, Mark Magdi Awad, Giulio Metro, Ilaria Attili, Fabiana Vitiello, Sara Pilotto, Stefania Gori, Giulio Rossi, Simonetta Buglioni, Diana Giannarelli, Lorenza Landi
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408535679